Welcare opens the new manufacturing plant in Orvieto

with a strategic €4.5 million investment

Infrastructure, technology and people at the heart of the 2028 industrial plan, to strengthen production and consolidate market positioning

Orvieto (TR), September 26, 2025 — **Welcare Industries**, part of the **Labomar Group** and a leading company in the production and distribution of medical devices, biocides, and customized solutions for patients and caregivers, inaugurated its new production facility today. The project, launched in August 2023 and completed in two years, required a **total investment of €4.5 million** and is part of a broader five-year industrial plan (2024–2028) aimed at supporting the company's growth.

The plan aims to consolidate Welcare's position as a center of excellence in the medical devices sector for the treatment of complex skin conditions of various aetiologies and for the prevention and management of healthcare-associated infections. The Company closed 2024 with growth — a performance driven by production expansion, technological innovation, energy efficiency, and sustainability — and aims to further increase its market share.

The new facility represents an expansion of Welcare's existing headquarters and is part of a continuous growth path, which had already seen significant expansions in production, logistics, and R&D areas in 2015 and 2017. The initiative is part of a broader investment project by the Group, aimed at accelerating growth, meeting the needs of an evolving global market, improving operational efficiency, and ensuring increasingly high-quality standards.

Fulvia Lazzarotto, CEO of Welcare Industries, states: *"The completion of the new production facility represents a strategic milestone in Welcare's growth journey and a targeted investment to strengthen our industrial capacity and competitiveness in international markets. From the very beginning, we have distinguished ourselves through curiosity, an international mindset, and a strong technological innovation drive—elements that have allowed us to develop high-value solutions for public health and well-being. The reality we have built is the result of ongoing and constructive dialogue with a diverse network of stakeholders: from local and regional institutions, to representatives of the healthcare system, our distribution partners, and the professionals and talents who, with competence and vision, have contributed to consolidating our presence on the international stage. Looking ahead, we aim to leverage these results to* *accelerate the Group's industrial development, expand our presence in global markets, and strengthen Welcare's position as a reference player for innovation, reliability, and sustainable growth, generating tangible and lasting value for all our stakeholders."*

"With this new production facility, we further strengthen the industrial ecosystem of our Group, giving substance to a clear long-term vision. It is also proof that innovation, sustainability, and integration among companies can generate shared value, positively impacting the market, the environment, and the communities in which we operate," says **Walter Bertin**, founder and CEO of Labomar. "*Welcare's journey, under the expert guidance of Fulvia Lazzarotto, is significant and constitutes a concrete example of how strategic vision and targeted investments can translate into development and shared value*."

The recent expansion has resulted in a **total production area of 600 m²**, hosting **two ISO-certified cleanrooms** dedicated to the production of medical devices and biocides in controlled environments. The **spaces dedicated to packaging** have also been expanded, now reaching 500 m², and an adjacent **800 m² building has been converted** into a logistics area. The offices, totalling **650 m²**, have undergone significant architectural and functional redevelopment.

From a technological standpoint, the facility has integrated **new automated lines** for the production of pre-impregnated wipes and gloves, and a second **autoclave for steam sterilization**, which doubles the thermal treatment capacity and ensures greater production flexibility.

Overall, the site activation is expected to **increase production capacity by over 50%**, thanks to greater automation, optimized internal flows, and increased operational space, responding to growing national and international demand.

The expansion project has also incorporated **energy efficiency solutions**: the **new photovoltaic system will provide an average of 60% of energy needs** during spring and summer months, while the **internal recycling and reuse system for technical water** will help reduce environmental impact. All these actions are consistent with Welcare's identity as a Benefit Corporation and certified B Corp™, committed to integrating ESG criteria and monitoring its environmental performance, including via Ecovadis ratings.

The investment will also have a significant impact on employment: the current workforce of **47 employees**, across production and offices, is expected to increase by approximately **20% in the medium term.** The **recruitment plan**, already underway, will unfold over the next **24 months**, opening **new positions in production, technical areas, and middle and senior management**, confirming Welcare's commitment to supporting industrial and employment growth in the Umbria region.